NOSA to acquire Deltamune’s laboratory business
Deal will create South Africa’s largest food, agriculture and occupational health laboratory group
NOSA Group, a leading global occupational health and safety (OHS) risk-management solutions provider, has signed an agreement to acquire 100 percent of the Deltamune Group’s laboratory business – a perceived leader in diagnostic testing and salmonella serotyping. The acquisition remains subject to standard closing conditions, and is expected to be finalised at the end of the month, becoming effective on December 1.
The acquisition follows NOSA’s 2017 procurement of the Centre for Scientific and Industrial Research’s (CSIR’s) Cape Town and Durban laboratories, and will position NOSA’s laboratory testing business – NOSA Testing – as South Africa’s largest group of laboratories focusing on food, agriculture and occupational health.
The combined testing business comprises eight laboratories located across the country, all of which are SANAS 17025 accredited, while two are DAFF approved for diagnostic testing within the poultry sector. The acquisition also gives NOSA Testing its first presence in the rest of Africa, through a laboratory in Zambia.
Pieter Erasmus, chief financial officer at NOSA, says NOSA’s Testing, Inspection and Certification (TIC) division offers unmatched technical expertise with regard to microbiological and chemical analysis, process and retail safety audits and ISO 22000 / FSSC 22000 certification.
“Post-acquisition, the laboratories will operate as usual, and over time we will enhance efficiencies across the testing network to better meet the stated needs of our clients,” says Erasmus.
“Through this acquisition and the combined portfolio of services it delivers, NOSA TIC is now able to bring increased scale and reach, an expanded range of technical solutions. It will become a regional partner for all our clients who are looking to improve and minimise their risk exposure across the food and agriculture value chain, as well as in the employee occupational health arena.”
Andre Munian, general manager of the Deltamune laboratory division, says: “This business combination allows us to better serve and understand our customers’ needs, while creating growth opportunities for our people.” He adds that the Deltamune Group will continue to serve its customers and their industries as a dedicated vaccine development and manufacturing company.